Type-I interferon receptor expression: Its circadian rhythm and downregulation after interferon-α administration in peripheral blood cells from renal cancer patients
Objectives: To investigate the regulation of interferon‐α (IFN‐α) receptor expression in metastatic renal cell carcinoma (RCC) after IFN‐α administration. Methods: Blood sampling was carried out in eight patients with metastatic RCC and six healthy volunteers. Flow‐cytometric analysis using a mono...
Gespeichert in:
| Veröffentlicht in: | International journal of urology 2009-04, Vol.16 (4), p.356-359 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 359 |
|---|---|
| container_issue | 4 |
| container_start_page | 356 |
| container_title | International journal of urology |
| container_volume | 16 |
| creator | Shiba, Masahiro Nonomura, Norio Nakai, Yasutomo Nakayama, Masashi Takayama, Hitoshi Inoue, Hitoshi Tsujimura, Akira Nishimura, Kazuo Okuyama, Akihiko |
| description | Objectives: To investigate the regulation of interferon‐α (IFN‐α) receptor expression in metastatic renal cell carcinoma (RCC) after IFN‐α administration.
Methods: Blood sampling was carried out in eight patients with metastatic RCC and six healthy volunteers. Flow‐cytometric analysis using a monoclonal antibody against the active subunit of the type‐I IFN‐α receptor (IFNAR2) was carried out to examine the circadian rhythm of IFNAR2 expression in peripheral blood mononuclear cells (PBMC) as well as its downregulation after IFN‐α administration.
Results: According to its circadian rhythm IFNAR2 in PBMC had a peak expression at night. Once IFN‐α is administered, IFNAR2 levels in PBMC showed downregulation within 48 h and recovered within another 48 h.
Conclusions: Our findings might support the establishment of an optimal schedule for IFN‐α administration. |
| doi_str_mv | 10.1111/j.1442-2042.2009.02265.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67197600</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20541417</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4655-4e17753d320ba4fc7cca77c0ed8f12ff00c200380929958402574adc8fcea6ef3</originalsourceid><addsrcrecordid>eNqNkdGO1CAUhonRuOPqKxiuvGsFSktr4oWZ6OxsNmrMrntJGHpwGFuo0MnOvJD3vojPJLWT1TvlBnL4_v_A-RHClOQ0rZe7nHLOMkY4yxkhTU4Yq8r88AAt7i8eogVpaJPVVLAz9CTGHSG0YLR-jM5oUxBWErFA36-PA2RrbN0IwUDwDgfQMIw-YDgMAWK03r3C6zFibYNWrVUJ2R7HbY-Va3Hr71yAL_tOjQnEyiSfv9yynz-wanvrbBzDjFiHBwh22EJQHd503rdYQ9dFbILvU3uXylo5nYyGJAE3xqfokVFdhGen_RzdvHt7vbzIrj6s1ss3V5nmVVlmHKgQZdEWjGwUN1porYTQBNraUGYMITqNq6hJw5qmrHkaguCq1bXRoCowxTl6MfsOwX_bQxxlb-P0OOXA76OsBG1ElSz-BTJScsqpSGA9gzr4GAMYOQTbq3CUlMgpTLmTU2ZyykxOYcrfYcpDkj4_9dhvemj_CE_pJeD1DNzZDo7_bSzXlzfTKemzWZ_CgcO9XoWv6aOFKOXt-5X8-Pn20-pSLOVF8QtANsHr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20541417</pqid></control><display><type>article</type><title>Type-I interferon receptor expression: Its circadian rhythm and downregulation after interferon-α administration in peripheral blood cells from renal cancer patients</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Shiba, Masahiro ; Nonomura, Norio ; Nakai, Yasutomo ; Nakayama, Masashi ; Takayama, Hitoshi ; Inoue, Hitoshi ; Tsujimura, Akira ; Nishimura, Kazuo ; Okuyama, Akihiko</creator><creatorcontrib>Shiba, Masahiro ; Nonomura, Norio ; Nakai, Yasutomo ; Nakayama, Masashi ; Takayama, Hitoshi ; Inoue, Hitoshi ; Tsujimura, Akira ; Nishimura, Kazuo ; Okuyama, Akihiko</creatorcontrib><description>Objectives: To investigate the regulation of interferon‐α (IFN‐α) receptor expression in metastatic renal cell carcinoma (RCC) after IFN‐α administration.
Methods: Blood sampling was carried out in eight patients with metastatic RCC and six healthy volunteers. Flow‐cytometric analysis using a monoclonal antibody against the active subunit of the type‐I IFN‐α receptor (IFNAR2) was carried out to examine the circadian rhythm of IFNAR2 expression in peripheral blood mononuclear cells (PBMC) as well as its downregulation after IFN‐α administration.
Results: According to its circadian rhythm IFNAR2 in PBMC had a peak expression at night. Once IFN‐α is administered, IFNAR2 levels in PBMC showed downregulation within 48 h and recovered within another 48 h.
Conclusions: Our findings might support the establishment of an optimal schedule for IFN‐α administration.</description><identifier>ISSN: 0919-8172</identifier><identifier>EISSN: 1442-2042</identifier><identifier>DOI: 10.1111/j.1442-2042.2009.02265.x</identifier><identifier>PMID: 19302507</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Publishing Asia</publisher><subject>Carcinoma, Renal Cell - blood ; Carcinoma, Renal Cell - drug therapy ; Circadian Rhythm ; Down-Regulation ; downregulation ; Humans ; Immunologic Factors - pharmacology ; Immunologic Factors - therapeutic use ; interferon ; Interferon-alpha - pharmacology ; Interferon-alpha - therapeutic use ; Kidney Neoplasms - blood ; Kidney Neoplasms - drug therapy ; Leukocytes, Mononuclear - drug effects ; Leukocytes, Mononuclear - metabolism ; receptor ; Receptor, Interferon alpha-beta - biosynthesis ; Receptor, Interferon alpha-beta - drug effects ; renal cell carcinoma</subject><ispartof>International journal of urology, 2009-04, Vol.16 (4), p.356-359</ispartof><rights>2009 The Japanese Urological Association</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4655-4e17753d320ba4fc7cca77c0ed8f12ff00c200380929958402574adc8fcea6ef3</citedby><cites>FETCH-LOGICAL-c4655-4e17753d320ba4fc7cca77c0ed8f12ff00c200380929958402574adc8fcea6ef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1442-2042.2009.02265.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1442-2042.2009.02265.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19302507$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shiba, Masahiro</creatorcontrib><creatorcontrib>Nonomura, Norio</creatorcontrib><creatorcontrib>Nakai, Yasutomo</creatorcontrib><creatorcontrib>Nakayama, Masashi</creatorcontrib><creatorcontrib>Takayama, Hitoshi</creatorcontrib><creatorcontrib>Inoue, Hitoshi</creatorcontrib><creatorcontrib>Tsujimura, Akira</creatorcontrib><creatorcontrib>Nishimura, Kazuo</creatorcontrib><creatorcontrib>Okuyama, Akihiko</creatorcontrib><title>Type-I interferon receptor expression: Its circadian rhythm and downregulation after interferon-α administration in peripheral blood cells from renal cancer patients</title><title>International journal of urology</title><addtitle>Int J Urol</addtitle><description>Objectives: To investigate the regulation of interferon‐α (IFN‐α) receptor expression in metastatic renal cell carcinoma (RCC) after IFN‐α administration.
Methods: Blood sampling was carried out in eight patients with metastatic RCC and six healthy volunteers. Flow‐cytometric analysis using a monoclonal antibody against the active subunit of the type‐I IFN‐α receptor (IFNAR2) was carried out to examine the circadian rhythm of IFNAR2 expression in peripheral blood mononuclear cells (PBMC) as well as its downregulation after IFN‐α administration.
Results: According to its circadian rhythm IFNAR2 in PBMC had a peak expression at night. Once IFN‐α is administered, IFNAR2 levels in PBMC showed downregulation within 48 h and recovered within another 48 h.
Conclusions: Our findings might support the establishment of an optimal schedule for IFN‐α administration.</description><subject>Carcinoma, Renal Cell - blood</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Circadian Rhythm</subject><subject>Down-Regulation</subject><subject>downregulation</subject><subject>Humans</subject><subject>Immunologic Factors - pharmacology</subject><subject>Immunologic Factors - therapeutic use</subject><subject>interferon</subject><subject>Interferon-alpha - pharmacology</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Kidney Neoplasms - blood</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Leukocytes, Mononuclear - drug effects</subject><subject>Leukocytes, Mononuclear - metabolism</subject><subject>receptor</subject><subject>Receptor, Interferon alpha-beta - biosynthesis</subject><subject>Receptor, Interferon alpha-beta - drug effects</subject><subject>renal cell carcinoma</subject><issn>0919-8172</issn><issn>1442-2042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkdGO1CAUhonRuOPqKxiuvGsFSktr4oWZ6OxsNmrMrntJGHpwGFuo0MnOvJD3vojPJLWT1TvlBnL4_v_A-RHClOQ0rZe7nHLOMkY4yxkhTU4Yq8r88AAt7i8eogVpaJPVVLAz9CTGHSG0YLR-jM5oUxBWErFA36-PA2RrbN0IwUDwDgfQMIw-YDgMAWK03r3C6zFibYNWrVUJ2R7HbY-Va3Hr71yAL_tOjQnEyiSfv9yynz-wanvrbBzDjFiHBwh22EJQHd503rdYQ9dFbILvU3uXylo5nYyGJAE3xqfokVFdhGen_RzdvHt7vbzIrj6s1ss3V5nmVVlmHKgQZdEWjGwUN1porYTQBNraUGYMITqNq6hJw5qmrHkaguCq1bXRoCowxTl6MfsOwX_bQxxlb-P0OOXA76OsBG1ElSz-BTJScsqpSGA9gzr4GAMYOQTbq3CUlMgpTLmTU2ZyykxOYcrfYcpDkj4_9dhvemj_CE_pJeD1DNzZDo7_bSzXlzfTKemzWZ_CgcO9XoWv6aOFKOXt-5X8-Pn20-pSLOVF8QtANsHr</recordid><startdate>200904</startdate><enddate>200904</enddate><creator>Shiba, Masahiro</creator><creator>Nonomura, Norio</creator><creator>Nakai, Yasutomo</creator><creator>Nakayama, Masashi</creator><creator>Takayama, Hitoshi</creator><creator>Inoue, Hitoshi</creator><creator>Tsujimura, Akira</creator><creator>Nishimura, Kazuo</creator><creator>Okuyama, Akihiko</creator><general>Blackwell Publishing Asia</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200904</creationdate><title>Type-I interferon receptor expression: Its circadian rhythm and downregulation after interferon-α administration in peripheral blood cells from renal cancer patients</title><author>Shiba, Masahiro ; Nonomura, Norio ; Nakai, Yasutomo ; Nakayama, Masashi ; Takayama, Hitoshi ; Inoue, Hitoshi ; Tsujimura, Akira ; Nishimura, Kazuo ; Okuyama, Akihiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4655-4e17753d320ba4fc7cca77c0ed8f12ff00c200380929958402574adc8fcea6ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Carcinoma, Renal Cell - blood</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Circadian Rhythm</topic><topic>Down-Regulation</topic><topic>downregulation</topic><topic>Humans</topic><topic>Immunologic Factors - pharmacology</topic><topic>Immunologic Factors - therapeutic use</topic><topic>interferon</topic><topic>Interferon-alpha - pharmacology</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Kidney Neoplasms - blood</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Leukocytes, Mononuclear - drug effects</topic><topic>Leukocytes, Mononuclear - metabolism</topic><topic>receptor</topic><topic>Receptor, Interferon alpha-beta - biosynthesis</topic><topic>Receptor, Interferon alpha-beta - drug effects</topic><topic>renal cell carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shiba, Masahiro</creatorcontrib><creatorcontrib>Nonomura, Norio</creatorcontrib><creatorcontrib>Nakai, Yasutomo</creatorcontrib><creatorcontrib>Nakayama, Masashi</creatorcontrib><creatorcontrib>Takayama, Hitoshi</creatorcontrib><creatorcontrib>Inoue, Hitoshi</creatorcontrib><creatorcontrib>Tsujimura, Akira</creatorcontrib><creatorcontrib>Nishimura, Kazuo</creatorcontrib><creatorcontrib>Okuyama, Akihiko</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shiba, Masahiro</au><au>Nonomura, Norio</au><au>Nakai, Yasutomo</au><au>Nakayama, Masashi</au><au>Takayama, Hitoshi</au><au>Inoue, Hitoshi</au><au>Tsujimura, Akira</au><au>Nishimura, Kazuo</au><au>Okuyama, Akihiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Type-I interferon receptor expression: Its circadian rhythm and downregulation after interferon-α administration in peripheral blood cells from renal cancer patients</atitle><jtitle>International journal of urology</jtitle><addtitle>Int J Urol</addtitle><date>2009-04</date><risdate>2009</risdate><volume>16</volume><issue>4</issue><spage>356</spage><epage>359</epage><pages>356-359</pages><issn>0919-8172</issn><eissn>1442-2042</eissn><abstract>Objectives: To investigate the regulation of interferon‐α (IFN‐α) receptor expression in metastatic renal cell carcinoma (RCC) after IFN‐α administration.
Methods: Blood sampling was carried out in eight patients with metastatic RCC and six healthy volunteers. Flow‐cytometric analysis using a monoclonal antibody against the active subunit of the type‐I IFN‐α receptor (IFNAR2) was carried out to examine the circadian rhythm of IFNAR2 expression in peripheral blood mononuclear cells (PBMC) as well as its downregulation after IFN‐α administration.
Results: According to its circadian rhythm IFNAR2 in PBMC had a peak expression at night. Once IFN‐α is administered, IFNAR2 levels in PBMC showed downregulation within 48 h and recovered within another 48 h.
Conclusions: Our findings might support the establishment of an optimal schedule for IFN‐α administration.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Publishing Asia</pub><pmid>19302507</pmid><doi>10.1111/j.1442-2042.2009.02265.x</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0919-8172 |
| ispartof | International journal of urology, 2009-04, Vol.16 (4), p.356-359 |
| issn | 0919-8172 1442-2042 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67197600 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Carcinoma, Renal Cell - blood Carcinoma, Renal Cell - drug therapy Circadian Rhythm Down-Regulation downregulation Humans Immunologic Factors - pharmacology Immunologic Factors - therapeutic use interferon Interferon-alpha - pharmacology Interferon-alpha - therapeutic use Kidney Neoplasms - blood Kidney Neoplasms - drug therapy Leukocytes, Mononuclear - drug effects Leukocytes, Mononuclear - metabolism receptor Receptor, Interferon alpha-beta - biosynthesis Receptor, Interferon alpha-beta - drug effects renal cell carcinoma |
| title | Type-I interferon receptor expression: Its circadian rhythm and downregulation after interferon-α administration in peripheral blood cells from renal cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T11%3A31%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Type-I%20interferon%20receptor%20expression:%20Its%20circadian%20rhythm%20and%20downregulation%20after%20interferon-%CE%B1%20administration%20in%20peripheral%20blood%20cells%20from%20renal%20cancer%20patients&rft.jtitle=International%20journal%20of%20urology&rft.au=Shiba,%20Masahiro&rft.date=2009-04&rft.volume=16&rft.issue=4&rft.spage=356&rft.epage=359&rft.pages=356-359&rft.issn=0919-8172&rft.eissn=1442-2042&rft_id=info:doi/10.1111/j.1442-2042.2009.02265.x&rft_dat=%3Cproquest_cross%3E20541417%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20541417&rft_id=info:pmid/19302507&rfr_iscdi=true |